Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Federal Reserve Faces Subpoena Delay Amid Investigation Into Chair Jerome Powell 
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
U.S. Condemns South Africa’s Expulsion of Israeli Diplomat Amid Rising Diplomatic Tensions 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Federal Judge Restores Funding for Gateway Rail Tunnel Project 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
